Seagen's high­est sell­ing drug snags a la­bel ex­pan­sion for pe­di­atric can­cer pa­tients

Seagen’s top-sell­ing drug just scored an­oth­er in­di­ca­tion, a few weeks af­ter ex­ecs boost­ed their full-year sales ex­pec­ta­tions.

The com­pa­ny’s Take­da-part­nered an­ti­body drug con­ju­gate Ad­cetris is now avail­able to pe­di­atric pa­tients 2 years and old­er with pre­vi­ous­ly un­treat­ed high-risk clas­si­cal Hodgkin’s lym­phoma (cHL), in com­bi­na­tion with a stan­dard-of-care chemother­a­py reg­i­men. That reg­i­men no­tably does not in­clude bleomycin, which has been linked to a high­er rate of lung tox­i­c­i­ty and was used in the six-drug con­trol arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER